Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Palladia
2. Su 11654
3. Su-11654
4. Su11654
1. 874819-74-6
2. Toceranib (phosphate)
3. Toceranib Phosphate [usan]
4. Pha-291639e
5. 24f9pf7j3r
6. (z)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-n-(2-(pyrrolidin-1-yl)ethyl)-1h-pyrrole-3-carboxamide Phosphate
7. Su11654
8. 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide;phosphoric Acid
9. Toceranib Phosphate (usan)
10. Su 11654
11. Su-11654
12. Pha291639
13. Unii-24f9pf7j3r
14. Su11654 Phosphate
15. Pha 291639 Phosphate
16. Chembl2103833
17. Toceranib Phosphate [mi]
18. Toceranib Phosphate(su 11654)
19. Hy-10330a
20. Mfcd25372034
21. S5272
22. Akos037645104
23. Ccg-269649
24. Cs-1231
25. Toceranib Phosphate [green Book]
26. As-57142
27. Bt162330
28. D08544
29. Q27253845
30. (z)-5-((5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl)-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide Phosphate
31. 1h-pyrrole-3-carboxamide, 5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-n-(2-(1-pyrrolidinyl)ethyl)-, Phosphate (1:1)
32. 5-((z)-(5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl)-2,4-dimethyl-n-(2-(pyrrolidin-1-yl)ethyl)-1h-pyrrole-3-carboxamide Phosphate (1:1)
Molecular Weight | 494.5 g/mol |
---|---|
Molecular Formula | C22H28FN4O6P |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 494.17304979 g/mol |
Monoisotopic Mass | 494.17304979 g/mol |
Topological Polar Surface Area | 155 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 713 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Toceranib Phosphate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Toceranib Phosphate, including repackagers and relabelers. The FDA regulates Toceranib Phosphate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Toceranib Phosphate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Toceranib Phosphate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Toceranib Phosphate supplier is an individual or a company that provides Toceranib Phosphate active pharmaceutical ingredient (API) or Toceranib Phosphate finished formulations upon request. The Toceranib Phosphate suppliers may include Toceranib Phosphate API manufacturers, exporters, distributors and traders.
click here to find a list of Toceranib Phosphate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Toceranib Phosphate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Toceranib Phosphate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Toceranib Phosphate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Toceranib Phosphate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Toceranib Phosphate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Toceranib Phosphate suppliers with NDC on PharmaCompass.
Toceranib Phosphate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Toceranib Phosphate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Toceranib Phosphate GMP manufacturer or Toceranib Phosphate GMP API supplier for your needs.
A Toceranib Phosphate CoA (Certificate of Analysis) is a formal document that attests to Toceranib Phosphate's compliance with Toceranib Phosphate specifications and serves as a tool for batch-level quality control.
Toceranib Phosphate CoA mostly includes findings from lab analyses of a specific batch. For each Toceranib Phosphate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Toceranib Phosphate may be tested according to a variety of international standards, such as European Pharmacopoeia (Toceranib Phosphate EP), Toceranib Phosphate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Toceranib Phosphate USP).
LOOKING FOR A SUPPLIER?